5/25/2010 12:16:11 PM
Vienna, Austria, 25 May, 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that MAM-06.301 has achieved preclinical proof of concept for the treatment of allergy and allergic asthma. The study is published in the online peer-reviewed journal “BMC Immunology”- www.biomedcentral.com/1471-2172/11/24.
The compound, also referred to as beta-escin, was identified through screening as a potential anti-allergic compound. In the present study, MAM-06.301 was investigated in vivo in two mouse models for early and late stage allergic reactions (passive cutaneous anaphylaxis and allergic asthma). In both models beta-escin showed a potent dose-dependent inhibitory effect.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “Serious allergies can be extremely debilitating life long problems and there is evidence that their incidence is increasing. The current array of treatment options such as steroids, antihistamines and mast-cell stabilizers suffer from issues of low patient compliance. We therefore hope that MAM-06.301 will be a safe alternative with high compliance in the future and plan to initiate a clinical trial in due course. "
The paper entitled “Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation” by Ines Lindner, Christiane Meier, Angelika Url, Hermann Unger, Andreas Grassauer, Eva Prieschl-Grassauer and Petra Doerfler appears online in the current issue of “BMC Immunology”- www.biomedcentral.com/1471-2172/11/24
About Marinomed Biotechnologie GmbH
Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray. The huge potential of the technology is reflected by Marinomed´s additional products concentrating on influenza, combination products for asthmatics and other high-risk patients. In addition, the Company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria. For further information please visit the website at www.marinomed.com
comments powered by